HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Quality in the field of pharmaceutical-grade biopolymers is reinforced through controlled processes, systematic monitoring, and continuous improvement across all stages of development and manufacturing. This perspective guided the recent ISO 13485 recertification audit at HTL Biotechnology’s industrial site, an important milestone in maintaining the robustness of our quality management system.
A Structured Assessment of Our Quality System
On September 30th and October 1st, GMED auditors conducted the renewal audit of our ISO 13485 certification for Hyaluronic Acid and Polynucleotides. This audit reflects the year-round work involved in meeting rigorous regulatory requirements, while ensuring best practices in the field of medical devices.
This ISO 13485 recertification guarantees the quality of the design and manufacturing of our medical devices, ensuring full compliance with regulatory and client requirements in terms of safety and efficacy.
A Result Reflecting Operational Discipline
This year’s audit concluded with no non-conformities, highlighting:
Sustaining Quality as Operations Evolve
The renewal of the ISO 13485 certification is not only a quality requirement, but also a foundation for the trust placed in us by our partners. As new biopolymers and production capabilities are added to our portfolio, quality management remains central to these developments.
Future process improvements, expansions, and product innovations will continue to be integrated within the same structured quality framework, ensuring alignment with regulatory expectations and industry best practices.
Looking Ahead
The successful renewal of ISO 13485 reflects the collective work of our teams involved in maintaining controlled, compliant, and efficient operations. It also reinforces the principles that guide our approach to manufacturing: consistency, purity, and commitment to improving quality over time.
With this recertification, our quality foundations remain strong as we continue to support the development and production of biopolymers for tomorrow’s medical needs.
To find out more about our excellence in quality :
Osteoarthritis is a degenerative joint disorder, often leading to chronic pain and reduced mobility as cartilage deteriorates over time.
Due to its viscoelastic properties, Hyaluronic acid (HA), a naturally occurring molecule in the body and a major component of the extracellular matrix, is an ideal candidate for addressing these degenerative processes of joint diseases. Recognized for its lubricating properties, HA is also shaping the management of osteoarthritis and rheumatologic diseases through its multi-faceted therapeutic potential.
Since 1992, HTL Biotechnology has pioneered hyaluronic acid (HA) production through bacterial fermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology, and rheumatology.